What is HC Wainwright's Estimate for MNMD Q1 Earnings?

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD - Free Report) - Research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for Mind Medicine (MindMed) in a research note issued on Wednesday, May 21st. HC Wainwright analyst P. Trucchio anticipates that the company will post earnings per share of ($0.38) for the quarter. HC Wainwright has a "Buy" rating and a $55.00 price objective on the stock. The consensus estimate for Mind Medicine (MindMed)'s current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for Mind Medicine (MindMed)'s Q2 2026 earnings at ($0.39) EPS, Q3 2026 earnings at ($0.39) EPS, Q4 2026 earnings at ($0.36) EPS and FY2029 earnings at $2.87 EPS.

Mind Medicine (MindMed) (NASDAQ:MNMD - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.01.

Other equities research analysts have also recently issued reports about the stock. Robert W. Baird reduced their target price on shares of Mind Medicine (MindMed) from $27.00 to $16.00 and set an "outperform" rating for the company in a report on Friday, March 7th. Evercore ISI began coverage on shares of Mind Medicine (MindMed) in a report on Tuesday, January 28th. They issued an "outperform" rating and a $23.00 target price on the stock. Chardan Capital reaffirmed a "buy" rating and set a $20.00 price target on shares of Mind Medicine (MindMed) in a research report on Friday, May 9th. Finally, Cantor Fitzgerald raised shares of Mind Medicine (MindMed) to a "strong-buy" rating in a research note on Tuesday, May 13th. Nine analysts have rated the stock with a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $25.11.

Mind Medicine (MindMed) Stock Down 2.2%

NASDAQ:MNMD traded down $0.16 during mid-day trading on Friday, hitting $7.14. The stock had a trading volume of 1,505,788 shares, compared to its average volume of 1,394,818. The stock has a 50-day simple moving average of $6.21 and a two-hundred day simple moving average of $6.97. The company has a market capitalization of $538.13 million, a PE ratio of -3.16 and a beta of 2.52. Mind Medicine has a twelve month low of $4.70 and a twelve month high of $10.44. The company has a current ratio of 9.00, a quick ratio of 9.00 and a debt-to-equity ratio of 0.09.

Hedge Funds Weigh In On Mind Medicine (MindMed)

A number of institutional investors have recently bought and sold shares of the stock. Diadema Partners LP acquired a new position in shares of Mind Medicine (MindMed) in the fourth quarter worth about $33,000. Hollencrest Capital Management boosted its stake in Mind Medicine (MindMed) by 10,833.3% in the 4th quarter. Hollencrest Capital Management now owns 7,216 shares of the company's stock worth $50,000 after purchasing an additional 7,150 shares during the period. Black Swift Group LLC acquired a new position in Mind Medicine (MindMed) in the 1st quarter worth approximately $63,000. CreativeOne Wealth LLC purchased a new position in Mind Medicine (MindMed) during the 1st quarter worth approximately $67,000. Finally, King Wealth Management Group acquired a new stake in Mind Medicine (MindMed) during the 4th quarter valued at $70,000. Hedge funds and other institutional investors own 27.91% of the company's stock.

Insider Activity at Mind Medicine (MindMed)

In other news, insider Daniel Karlin sold 6,836 shares of the stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $6.74, for a total transaction of $46,074.64. Following the completion of the sale, the insider now owns 446,177 shares in the company, valued at approximately $3,007,232.98. This represents a 1.51% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Robert Barrow sold 21,208 shares of the firm's stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $6.74, for a total value of $142,941.92. Following the sale, the chief executive officer now directly owns 856,556 shares of the company's stock, valued at approximately $5,773,187.44. This represents a 2.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 30,391 shares of company stock valued at $204,835 over the last ninety days. Insiders own 2.45% of the company's stock.

About Mind Medicine (MindMed)

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.